idea-007 · vet · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. An implanted port that lets an owner give a cat with kidney disease its fluids without a needle each time. Cats with chronic kidney disease need fluid under the skin several times a week, usually for the rest of their lives, and most owners do it at home with a needle and a bag. It is unpleasant for the cat and many owners skip sessions. This device is a small port placed under the skin in a short operation, with a soft perforated tube that spreads the fluid; the owner connects a pre-measured giving set to the port instead of inserting a needle. Its two design bets are a surface chemistry meant to keep the body from reacting to the implant over years, and a metered giving set that makes each session a fixed dose. There is no FDA premarket review for animal devices and no insurance — the owner pays.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read PMID 40011049 — the SUB long-term outcomes study — closely enough to establish whether the chronic device mineralization it reports in 19-50% of implants is a urine-chemistry phenomenon that would not transfer to a port carrying crystalloid, or a surface-and-dwell-time phenomenon that would. The file's gap analysis names the SUB precedent as the nearest available proxy for how an implanted feline port behaves over years; this is the specific question that proxy now raises. One hour of reading, standing in front of a multi-year study, and it changes the material-qualification programme, the case-series design and the moat argument at once. Selected from the Mechanism and Moat rows' gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 2 of 39 claims verified, 37 unconfirmed, none refuted — the thinnest verified position in the wrapped set alongside idea-004. All 9 factors carry a score in the Stage 2 triage table and all 4 core factors do.
Both verified claims are regulatory classification: veterinary-only manufacturers need not register or list devices with FDA [claim 2: verified], and human implanted vascular access ports are Class II under 21 CFR 880.5965, product code PXK [claim 36: verified]. No commercial claim in this file has ever been verified, and on current tooling none can be — the connectors that produce real numbers elsewhere in this pipeline are CMS and openFDA, and neither sees a veterinary market. An empty FDA scan here is coverage absence, never competitive absence.
Eleven claims were added by the research lane since 2026-08-24 and not one moved a tag. They nevertheless spent this candidate's previously-named cheapest next test, and the results matter in three directions.
Demand is now the best-evidenced part of the file. In a survey of 468 owners of CKD cats, 399 (85%) were giving subcutaneous fluids at home [claim 29: unconfirmed], and among those, 155 of 399 (39%) reported skipping doses in the prior 2-4 weeks because their cat was frustrated [claim 30: unconfirmed]. The premise this product is built on — that the needle regimen lapses — is measured rather than assumed.
The nearest device precedent was read, and it is two-sided. The previous decks said three times that the subcutaneous ureteral bypass literature had been "located by title, never read". It has been. In 95 SUB devices across 66 cats, chronic device mineralization occurred in 19-50% of devices and chronic urinary tract infection in 3-33% of cats, varying with flush protocol [claim 32: unconfirmed]. Against that, comparing device generations in 80 cats, catheter kinking fell from 15.5% to 0% and 90-day survival rose from 75% to 94% [claim 33: unconfirmed] — implanted feline ports have characterisable, improvable failure modes, and the incumbent is actively improving them. Human implanted ports are reassuring by comparison — 0.05 catheter-related bloodstream infections per 1,000 catheter-days [claim 34: unconfirmed], early infection in 1.2% of 1,714 placements [claim 35: unconfirmed] — but those are clinician-accessed ports, not ports accessed by an untrained owner at a kitchen table several times a week.
A second clock appeared that the capital plan does not carry. The file prices a case series as a line item against an oncologic endpoint that needs years. The SUB record says a device-durability problem would land first and could end the programme on its own. Costing one series against one endpoint understates both the money and the calendar.
Two cautions on reading the rest. The two prevalence figures the research lane returned are not reconcilable at face value — 50% in a US feline-only practice cohort [claim 38: unconfirmed] against 1.2% in a UK primary-care cohort of 353,448 cats [claim 39: unconfirmed] — because they are answering different questions, and a TAM built on either without saying which is a number without a meaning. And FTO is unexamined rather than clear [claim 28: unconfirmed]: never asked, on the rubric's one automatic-kill factor, against an incumbent that is demonstrably an active device developer in this exact species and anatomy. On a candidate whose only other barrier to entry is tooling, the patent position is the whole defence.
| Intended use | For placement by a licensed veterinarian to provide repeated subcutaneous administration of isotonic crystalloid fluids by the owner at home, in cats with chronic kidney disease requiring ongoing fluid therapy, as an alternative to repeated percutaneous needle sticks. |
|---|---|
| Mechanism | Implanted fenestrated silicone or low-fouling-polymer diffuser placed in the subcutaneous space with a septum port at a defined, palpable, non-interscapular site, accessed by a metered owner-operated giving set that delivers a fixed volume per session without a hanging fluid bag or a free needle |
| Device class | # Premarket classification genuinely has no referent here, and; n/a — the device is labelled for veterinary use only, and FDA does not classify or; review animal-only devices premarket. n/a is used in the sense the template intends:; no referent, not "unknown."; Class II — 510(k) — NOT live, and named only to fix the boundary: an implanted; subcutaneous vascular or infusion access port for human use is a regulated Class II; device with a crowded predicate field and a live patent estate. Any human-use claim on; this hardware moves it there, into a different and far more capital-intensive business. |
| Predicate or analog | Subcutaneous fluid ports already used in feline practice (fenestrated; silicone tubing with a subcutaneous port, marketed as a needleless; long-term alternative to daily subcutaneous fluid injections). Adjacent; but distinct: the subcutaneous ureteral bypass (SUB) device, which is an; implanted port system for ureteral obstruction, not for hydration; therapy, and is cited here as an existence proof that feline owners and; surgeons already accept an implanted port with lifelong percutaneous; access. |
| Launch jurisdiction | US |
| Target | vet |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 5 | Claim 2 is reachable: regulation connector on 21 CFR 807.65 (exemption from registration/listing), the same lookup idea-002 reports as verified for a similarly-worded claim — re-run it here, do not inherit the tag. Claim 1 is…the rest of this gap analysisnot reachable by any connector in this repo: the premarket-exemption position lives in FDA Compliance Policy Guide text (CPG Sec. 300.100 / 7124.29 territory), which no connector serves; idea-002 already came backunconfirmed on it for exactly that reason. Resolving claim 1 needs a human to attach the CPG text or regulatory-counsel opinion. openFDA will never help — it holds no records for animal-only devices. |
| Reimbursement pathway | 1 | Nothing can settle this and nothing should be queued. hcpcs, payment_rates and coverage_policies all query CMS, which has no jurisdiction over veterinary care; a null from them is a category error, not a finding, and must not be…the rest of this gap analysisread as "no code found." Do not send this row to Stage 3. The only thing a human could usefully attach is commercial context, not a code: pet-insurance attachment rate and typical reimbursement for CKD fluid therapy (NAPHIA state-of-the-industry report, licensed), and practice-level cash pricing from a veterinary distributor catalogue. Treat this row as closed at Stage 2 and mark it so at Stage 4. |
| TAM | 2 | Component 1 (claim 8): no connector reaches this. procedure_volumes reads CMS files, which cover no animal care; there is no veterinary equivalent. Requires a human to attach veterinary epidemiology — VetCompass US, or Banfield/Mars…the rest of this gap analysisState of Pet Health prevalence tables — the same permanent gap idea-002 logs for canine caseload. Component 2 (claim 9): human-attachable and cheap — a current veterinary distributor catalogue (Covetrus, Patterson Vet, MWI) gives real net-to-practice pricing for existing feline subQ port kits and giving sets; this is the one TAM input that can be made real without a licensed report. Component 3 (claim 10): unreachable by any source, connector or licensed — it is a demand assumption that only a practice survey or a pilot would test. |
| FTO / IP | *(blank — no claim)* | patents connector, searching implanted subcutaneous infusion/fluid-access ports, fenestrated subcutaneous diffusers, low-fouling implant surface chemistries, and metered/fixed-volume giving sets. **Critical asymmetry to hold onto: FDA's…the rest of this gap analysisabsence from animal-only devices does not extend to patents.** A live US patent claiming an implanted subcutaneous port is enforceable against a device labelled for veterinary use exactly as it is against a human-use one, so the human-side patent estate flagged indevice_class is a direct FTO threat to this candidate, not a neighbouring field. Also worth a specific look at the SUB device manufacturer's US estate (claim 6 names the analog). This is the one core factor here that a connector can fully resolve — queue it first. |
| Moat / defensibility | 2 | Partly connector-reachable, partly not. The patentability half is testable now via the patents connector as prior-art search on the two named levers (low-fouling/antifouling surface chemistry on implanted silicone, fixed-volume metered…the rest of this gap analysisgiving sets) — the same invocation that serves Factor 4, read for a different purpose. The rest is not connector-checkable as written and does not become so with more searching: switching costs, veterinarian implant-training lock-in, and distributor relationships are commercial judgements. Settled only by a filed provisional with real claim language reviewed by patent counsel (Tier 3), not by any lookup. |
| Mechanism & clinical risk | 2 | literature connector on PMC11383148 to confirm claim 4 exists and says what is claimed — note this returns a ScanResult with no confidence tag and no ability to acquire one, so it establishes bibliographic existence only and can…the rest of this gap analysisnever make this factor's risk quantified. Claim 5 needs a realliterature pass on feline injection-site sarcoma incidence and its association with chronic inflammation at implant sites, plus the WHO/VCS vaccine-site-sarcoma literature. Claim 6's SUB long-term complication rates are readable from the PMC records the Generator surfaced by title but never opened. The thing that would actually settle Factor 13 exists in no literature and no connector: a prospective feline case series with multi-year follow-up powered to say something about tumour incidence at this implant site — Tier 3, and it is also what sets the calendar in the row below. |
| Capital intensity & time-to-revenue | 3 | Cost side is human-attachable and reasonably cheap: quotes for ISO 10993 biocompatibility testing on the implant material, ISO 11607 sterile barrier validation, and silicone/polymer moulding tooling from a contract manufacturer. Calendar…the rest of this gap analysisside is settled by a veterinary teaching-hospital study protocol and IACUC timeline — Tier 3, obtained from a partner institution, and not reachable by any connector. No connector in this repo estimates cost or time for anything; treat this row as permanently human-attached. |
| Competitive intensity | 2 | **Structural blindness, flagged by claim 15 and worth restating so no future scan misreads it: clearances and recalls query openFDA, which holds no records for animal-only devices. A none from either is coverage absence, not…the rest of this gap analysiscompetitive absence, and must never be logged as an all-clear on the veterinary field.** The signal log already records this gap for idea-002. Real answers come from human-attached veterinary trade sources: distributor catalogues (Covetrus, Patterson Vet, MWI) for what is actually marketed, VMX/WVC exhibitor lists, and ACVIM/ACVS abstract books. Thepatents connector is the one exception that sees this field honestly, since patent records do not respect the human/vet labelling boundary. |
| Strategic fit & portfolio balance | *(blank — no claim, no referent)* | Not a research gap and not a Stage 3 work item — a Tier 3 input that does not exist yet. Settled only by a human stating the portfolio thesis and capital allocation posture, at Stage 6 shortlist review. No connector, no literature and…the rest of this gap analysisno licensed report can supply it. If a portfolio-state document is ever added toknowledge-base/, this row becomes scorable at Stage 2 for every candidate; until then expect it blank across the board. |
All six wrap criteria are met.
Domain dossier: feline-ckd-subcutaneous-fluid-therapy
Source file: knowledge-base/candidates/idea-007.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.